img

Global Hereditary Angioedema Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Hereditary Angioedema Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The global Hereditary Angioedema Treatment market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Hereditary Angioedema Treatment is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Hereditary Angioedema Treatment is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Hereditary Angioedema Treatment is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Hereditary Angioedema Treatment include CSL, Pharming Group, Shire plc (Takeda Pharmaceutical Company Limited), Ionis Pharmaceuticals, Attune Pharmaceuticals, BioCryst Pharmaceuticals and KalVista Pharmaceuticals, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Hereditary Angioedema Treatment, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Hereditary Angioedema Treatment by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Hereditary Angioedema Treatment market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Hereditary Angioedema Treatment market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


CSL
Pharming Group
Shire plc (Takeda Pharmaceutical Company Limited)
Ionis Pharmaceuticals
Attune Pharmaceuticals
BioCryst Pharmaceuticals
KalVista Pharmaceuticals
By Type
C1 Estearse Inhibitors (Plasma Products, Recombinant Products)
Selective Bradykinin B2 Receptor Antagonists (Firazyr)
Kallikrein Inhibitors (Kalbitor, Takhzyro)
Others (Conventional Drugs, Pipeline Drugs)
By Application
Hospital Pharmacies
Retail Pharmacies
Others (online pharmacies, mail pharmacies)
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Hereditary Angioedema Treatment in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Hereditary Angioedema Treatment manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hereditary Angioedema Treatment sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Hereditary Angioedema Treatment Definition
1.2 Market by Type
1.2.1 Global Hereditary Angioedema Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 C1 Estearse Inhibitors (Plasma Products, Recombinant Products)
1.2.3 Selective Bradykinin B2 Receptor Antagonists (Firazyr)
1.2.4 Kallikrein Inhibitors (Kalbitor, Takhzyro)
1.2.5 Others (Conventional Drugs, Pipeline Drugs)
1.3 Market Segment by Application
1.3.1 Global Hereditary Angioedema Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Others (online pharmacies, mail pharmacies)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Hereditary Angioedema Treatment Sales
2.1 Global Hereditary Angioedema Treatment Revenue Estimates and Forecasts 2018-2034
2.2 Global Hereditary Angioedema Treatment Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Hereditary Angioedema Treatment Revenue by Region
2.3.1 Global Hereditary Angioedema Treatment Revenue by Region (2018-2024)
2.3.2 Global Hereditary Angioedema Treatment Revenue by Region (2024-2034)
2.4 Global Hereditary Angioedema Treatment Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Hereditary Angioedema Treatment Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Hereditary Angioedema Treatment Sales Quantity by Region
2.6.1 Global Hereditary Angioedema Treatment Sales Quantity by Region (2018-2024)
2.6.2 Global Hereditary Angioedema Treatment Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Hereditary Angioedema Treatment Sales Quantity by Manufacturers
3.1.1 Global Hereditary Angioedema Treatment Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Hereditary Angioedema Treatment Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Hereditary Angioedema Treatment Sales in 2022
3.2 Global Hereditary Angioedema Treatment Revenue by Manufacturers
3.2.1 Global Hereditary Angioedema Treatment Revenue by Manufacturers (2018-2024)
3.2.2 Global Hereditary Angioedema Treatment Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Hereditary Angioedema Treatment Revenue in 2022
3.3 Global Hereditary Angioedema Treatment Sales Price by Manufacturers
3.4 Global Key Players of Hereditary Angioedema Treatment, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Hereditary Angioedema Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Hereditary Angioedema Treatment, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Hereditary Angioedema Treatment, Product Offered and Application
3.8 Global Key Manufacturers of Hereditary Angioedema Treatment, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Hereditary Angioedema Treatment Sales Quantity by Type
4.1.1 Global Hereditary Angioedema Treatment Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Hereditary Angioedema Treatment Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Hereditary Angioedema Treatment Sales Quantity Market Share by Type (2018-2034)
4.2 Global Hereditary Angioedema Treatment Revenue by Type
4.2.1 Global Hereditary Angioedema Treatment Historical Revenue by Type (2018-2024)
4.2.2 Global Hereditary Angioedema Treatment Forecasted Revenue by Type (2024-2034)
4.2.3 Global Hereditary Angioedema Treatment Revenue Market Share by Type (2018-2034)
4.3 Global Hereditary Angioedema Treatment Price by Type
4.3.1 Global Hereditary Angioedema Treatment Price by Type (2018-2024)
4.3.2 Global Hereditary Angioedema Treatment Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Hereditary Angioedema Treatment Sales Quantity by Application
5.1.1 Global Hereditary Angioedema Treatment Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Hereditary Angioedema Treatment Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Hereditary Angioedema Treatment Sales Quantity Market Share by Application (2018-2034)
5.2 Global Hereditary Angioedema Treatment Revenue by Application
5.2.1 Global Hereditary Angioedema Treatment Historical Revenue by Application (2018-2024)
5.2.2 Global Hereditary Angioedema Treatment Forecasted Revenue by Application (2024-2034)
5.2.3 Global Hereditary Angioedema Treatment Revenue Market Share by Application (2018-2034)
5.3 Global Hereditary Angioedema Treatment Price by Application
5.3.1 Global Hereditary Angioedema Treatment Price by Application (2018-2024)
5.3.2 Global Hereditary Angioedema Treatment Price Forecast by Application (2024-2034)
6 North America
6.1 North America Hereditary Angioedema Treatment Sales by Company
6.1.1 North America Hereditary Angioedema Treatment Revenue by Company (2018-2024)
6.1.2 North America Hereditary Angioedema Treatment Sales Quantity by Company (2018-2024)
6.2 North America Hereditary Angioedema Treatment Market Size by Type
6.2.1 North America Hereditary Angioedema Treatment Sales Quantity by Type (2018-2034)
6.2.2 North America Hereditary Angioedema Treatment Revenue by Type (2018-2034)
6.3 North America Hereditary Angioedema Treatment Market Size by Application
6.3.1 North America Hereditary Angioedema Treatment Sales Quantity by Application (2018-2034)
6.3.2 North America Hereditary Angioedema Treatment Revenue by Application (2018-2034)
6.4 North America Hereditary Angioedema Treatment Market Size by Country
6.4.1 North America Hereditary Angioedema Treatment Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Hereditary Angioedema Treatment Revenue by Country (2018-2034)
6.4.3 North America Hereditary Angioedema Treatment Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Hereditary Angioedema Treatment Sales by Company
7.1.1 Europe Hereditary Angioedema Treatment Sales Quantity by Company (2018-2024)
7.1.2 Europe Hereditary Angioedema Treatment Revenue by Company (2018-2024)
7.2 Europe Hereditary Angioedema Treatment Market Size by Type
7.2.1 Europe Hereditary Angioedema Treatment Sales Quantity by Type (2018-2034)
7.2.2 Europe Hereditary Angioedema Treatment Revenue by Type (2018-2034)
7.3 Europe Hereditary Angioedema Treatment Market Size by Application
7.3.1 Europe Hereditary Angioedema Treatment Sales Quantity by Application (2018-2034)
7.3.2 Europe Hereditary Angioedema Treatment Revenue by Application (2018-2034)
7.4 Europe Hereditary Angioedema Treatment Market Size by Country
7.4.1 Europe Hereditary Angioedema Treatment Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Hereditary Angioedema Treatment Revenue by Country (2018-2034)
7.4.3 Europe Hereditary Angioedema Treatment Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Hereditary Angioedema Treatment Sales by Company
8.1.1 China Hereditary Angioedema Treatment Sales Quantity by Company (2018-2024)
8.1.2 China Hereditary Angioedema Treatment Revenue by Company (2018-2024)
8.2 China Hereditary Angioedema Treatment Market Size by Type
8.2.1 China Hereditary Angioedema Treatment Sales Quantity by Type (2018-2034)
8.2.2 China Hereditary Angioedema Treatment Revenue by Type (2018-2034)
8.3 China Hereditary Angioedema Treatment Market Size by Application
8.3.1 China Hereditary Angioedema Treatment Sales Quantity by Application (2018-2034)
8.3.2 China Hereditary Angioedema Treatment Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Hereditary Angioedema Treatment Sales by Company
9.1.1 APAC Hereditary Angioedema Treatment Sales Quantity by Company (2018-2024)
9.1.2 APAC Hereditary Angioedema Treatment Revenue by Company (2018-2024)
9.2 APAC Hereditary Angioedema Treatment Market Size by Type
9.2.1 APAC Hereditary Angioedema Treatment Sales Quantity by Type (2018-2034)
9.2.2 APAC Hereditary Angioedema Treatment Revenue by Type (2018-2034)
9.3 APAC Hereditary Angioedema Treatment Market Size by Application
9.3.1 APAC Hereditary Angioedema Treatment Sales Quantity by Application (2018-2034)
9.3.2 APAC Hereditary Angioedema Treatment Revenue by Application (2018-2034)
9.4 APAC Hereditary Angioedema Treatment Market Size by Region
9.4.1 APAC Hereditary Angioedema Treatment Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Hereditary Angioedema Treatment Revenue by Region (2018-2034)
9.4.3 APAC Hereditary Angioedema Treatment Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales by Company
10.1.1 Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Hereditary Angioedema Treatment Market Size by Type
10.2.1 Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Hereditary Angioedema Treatment Market Size by Application
10.3.1 Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Hereditary Angioedema Treatment Market Size by Country
10.4.1 Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 CSL
11.1.1 CSL Company Information
11.1.2 CSL Overview
11.1.3 CSL Hereditary Angioedema Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 CSL Hereditary Angioedema Treatment Products and Services
11.1.5 CSL Hereditary Angioedema Treatment SWOT Analysis
11.1.6 CSL Recent Developments
11.2 Pharming Group
11.2.1 Pharming Group Company Information
11.2.2 Pharming Group Overview
11.2.3 Pharming Group Hereditary Angioedema Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Pharming Group Hereditary Angioedema Treatment Products and Services
11.2.5 Pharming Group Hereditary Angioedema Treatment SWOT Analysis
11.2.6 Pharming Group Recent Developments
11.3 Shire plc (Takeda Pharmaceutical Company Limited)
11.3.1 Shire plc (Takeda Pharmaceutical Company Limited) Company Information
11.3.2 Shire plc (Takeda Pharmaceutical Company Limited) Overview
11.3.3 Shire plc (Takeda Pharmaceutical Company Limited) Hereditary Angioedema Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Shire plc (Takeda Pharmaceutical Company Limited) Hereditary Angioedema Treatment Products and Services
11.3.5 Shire plc (Takeda Pharmaceutical Company Limited) Hereditary Angioedema Treatment SWOT Analysis
11.3.6 Shire plc (Takeda Pharmaceutical Company Limited) Recent Developments
11.4 Ionis Pharmaceuticals
11.4.1 Ionis Pharmaceuticals Company Information
11.4.2 Ionis Pharmaceuticals Overview
11.4.3 Ionis Pharmaceuticals Hereditary Angioedema Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Ionis Pharmaceuticals Hereditary Angioedema Treatment Products and Services
11.4.5 Ionis Pharmaceuticals Hereditary Angioedema Treatment SWOT Analysis
11.4.6 Ionis Pharmaceuticals Recent Developments
11.5 Attune Pharmaceuticals
11.5.1 Attune Pharmaceuticals Company Information
11.5.2 Attune Pharmaceuticals Overview
11.5.3 Attune Pharmaceuticals Hereditary Angioedema Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Attune Pharmaceuticals Hereditary Angioedema Treatment Products and Services
11.5.5 Attune Pharmaceuticals Hereditary Angioedema Treatment SWOT Analysis
11.5.6 Attune Pharmaceuticals Recent Developments
11.6 BioCryst Pharmaceuticals
11.6.1 BioCryst Pharmaceuticals Company Information
11.6.2 BioCryst Pharmaceuticals Overview
11.6.3 BioCryst Pharmaceuticals Hereditary Angioedema Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 BioCryst Pharmaceuticals Hereditary Angioedema Treatment Products and Services
11.6.5 BioCryst Pharmaceuticals Hereditary Angioedema Treatment SWOT Analysis
11.6.6 BioCryst Pharmaceuticals Recent Developments
11.7 KalVista Pharmaceuticals
11.7.1 KalVista Pharmaceuticals Company Information
11.7.2 KalVista Pharmaceuticals Overview
11.7.3 KalVista Pharmaceuticals Hereditary Angioedema Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 KalVista Pharmaceuticals Hereditary Angioedema Treatment Products and Services
11.7.5 KalVista Pharmaceuticals Hereditary Angioedema Treatment SWOT Analysis
11.7.6 KalVista Pharmaceuticals Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Hereditary Angioedema Treatment Value Chain Analysis
12.2 Hereditary Angioedema Treatment Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Hereditary Angioedema Treatment Production Mode & Process
12.4 Hereditary Angioedema Treatment Sales and Marketing
12.4.1 Hereditary Angioedema Treatment Sales Channels
12.4.2 Hereditary Angioedema Treatment Distributors
12.5 Hereditary Angioedema Treatment Customers
13 Market Dynamics
13.1 Hereditary Angioedema Treatment Industry Trends
13.2 Hereditary Angioedema Treatment Market Drivers
13.3 Hereditary Angioedema Treatment Market Challenges
13.4 Hereditary Angioedema Treatment Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Hereditary Angioedema Treatment Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of C1 Estearse Inhibitors (Plasma Products, Recombinant Products)
Table 3. Major Manufacturers of Selective Bradykinin B2 Receptor Antagonists (Firazyr)
Table 4. Major Manufacturers of Kallikrein Inhibitors (Kalbitor, Takhzyro)
Table 5. Major Manufacturers of Others (Conventional Drugs, Pipeline Drugs)
Table 6. Global Hereditary Angioedema Treatment Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Hereditary Angioedema Treatment Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Hereditary Angioedema Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Hereditary Angioedema Treatment Revenue Market Share by Region (2018-2024)
Table 10. Global Hereditary Angioedema Treatment Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Hereditary Angioedema Treatment Revenue Market Share by Region (2024-2034)
Table 12. Global Hereditary Angioedema Treatment Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 13. Global Hereditary Angioedema Treatment Sales by Region (2018-2024) & (K Units)
Table 14. Global Hereditary Angioedema Treatment Sales Market Share by Region (2018-2024)
Table 15. Global Hereditary Angioedema Treatment Sales by Region (2024-2034) & (K Units)
Table 16. Global Hereditary Angioedema Treatment Sales Market Share by Region (2024-2034)
Table 17. Global Hereditary Angioedema Treatment Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 18. Global Hereditary Angioedema Treatment Sales Quantity Share by Manufacturers (2018-2024)
Table 19. Global Hereditary Angioedema Treatment Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Hereditary Angioedema Treatment Revenue Share by Manufacturers (2018-2024)
Table 21. Global Hereditary Angioedema Treatment Price by Manufacturers 2018-2024 (USD/Unit)
Table 22. Global Key Players of Hereditary Angioedema Treatment, Industry Ranking, 2021 VS 2022
Table 23. Global Hereditary Angioedema Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Hereditary Angioedema Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hereditary Angioedema Treatment as of 2022)
Table 25. Global Key Manufacturers of Hereditary Angioedema Treatment, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Hereditary Angioedema Treatment, Product Offered and Application
Table 27. Global Key Manufacturers of Hereditary Angioedema Treatment, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Hereditary Angioedema Treatment Sales Quantity by Type (2018-2024) & (K Units)
Table 30. Global Hereditary Angioedema Treatment Sales Quantity by Type (2024-2034) & (K Units)
Table 31. Global Hereditary Angioedema Treatment Sales Quantity Share by Type (2018-2024)
Table 32. Global Hereditary Angioedema Treatment Sales Quantity Share by Type (2024-2034)
Table 33. Global Hereditary Angioedema Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Hereditary Angioedema Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Hereditary Angioedema Treatment Revenue Share by Type (2018-2024)
Table 36. Global Hereditary Angioedema Treatment Revenue Share by Type (2024-2034)
Table 37. Hereditary Angioedema Treatment Price by Type (2018-2024) & (USD/Unit)
Table 38. Global Hereditary Angioedema Treatment Price Forecast by Type (2024-2034) & (USD/Unit)
Table 39. Global Hereditary Angioedema Treatment Sales Quantity by Application (2018-2024) & (K Units)
Table 40. Global Hereditary Angioedema Treatment Sales Quantity by Application (2024-2034) & (K Units)
Table 41. Global Hereditary Angioedema Treatment Sales Quantity Share by Application (2018-2024)
Table 42. Global Hereditary Angioedema Treatment Sales Quantity Share by Application (2024-2034)
Table 43. Global Hereditary Angioedema Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Hereditary Angioedema Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Hereditary Angioedema Treatment Revenue Share by Application (2018-2024)
Table 46. Global Hereditary Angioedema Treatment Revenue Share by Application (2024-2034)
Table 47. Hereditary Angioedema Treatment Price by Application (2018-2024) & (USD/Unit)
Table 48. Global Hereditary Angioedema Treatment Price Forecast by Application (2024-2034) & (USD/Unit)
Table 49. North America Hereditary Angioedema Treatment Revenue by Company (2018-2024) & (US$ Million)
Table 50. North America Hereditary Angioedema Treatment Sales Quantity by Company (2018-2024) & (K Units)
Table 51. North America Hereditary Angioedema Treatment Sales Quantity by Type (2018-2024) & (K Units)
Table 52. North America Hereditary Angioedema Treatment Sales Quantity by Type (2024-2034) & (K Units)
Table 53. North America Hereditary Angioedema Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 54. North America Hereditary Angioedema Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Hereditary Angioedema Treatment Sales Quantity by Application (2018-2024) & (K Units)
Table 56. North America Hereditary Angioedema Treatment Sales Quantity by Application (2024-2034) & (K Units)
Table 57. North America Hereditary Angioedema Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 58. North America Hereditary Angioedema Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Hereditary Angioedema Treatment Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 60. North America Hereditary Angioedema Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 61. North America Hereditary Angioedema Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Hereditary Angioedema Treatment Sales Quantity by Country (2018-2024) & (K Units)
Table 63. North America Hereditary Angioedema Treatment Sales Quantity by Country (2024-2034) & (K Units)
Table 64. Europe Hereditary Angioedema Treatment Sales Quantity by Company (2018-2024) & (K Units)
Table 65. Europe Hereditary Angioedema Treatment Revenue by Company (2018-2024) & (US$ Million)
Table 66. Europe Hereditary Angioedema Treatment Sales Quantity by Type (2018-2024) & (K Units)
Table 67. Europe Hereditary Angioedema Treatment Sales Quantity by Type (2024-2034) & (K Units)
Table 68. Europe Hereditary Angioedema Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Hereditary Angioedema Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Hereditary Angioedema Treatment Sales Quantity by Application (2018-2024) & (K Units)
Table 71. Europe Hereditary Angioedema Treatment Sales Quantity by Application (2024-2034) & (K Units)
Table 72. Europe Hereditary Angioedema Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Hereditary Angioedema Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Hereditary Angioedema Treatment Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 75. Europe Hereditary Angioedema Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Hereditary Angioedema Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Hereditary Angioedema Treatment Sales Quantity by Country (2018-2024) & (K Units)
Table 78. Europe Hereditary Angioedema Treatment Sales Quantity by Country (2024-2034) & (K Units)
Table 79. China Hereditary Angioedema Treatment Sales Quantity by Company (2018-2024) & (K Units)
Table 80. China Hereditary Angioedema Treatment Revenue by Company (2018-2024) & (US$ Million)
Table 81. China Hereditary Angioedema Treatment Sales Quantity by Type (2018-2024) & (K Units)
Table 82. China Hereditary Angioedema Treatment Sales Quantity by Type (2024-2034) & (K Units)
Table 83. China Hereditary Angioedema Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 84. China Hereditary Angioedema Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Hereditary Angioedema Treatment Sales Quantity by Application (2018-2024) & (K Units)
Table 86. China Hereditary Angioedema Treatment Sales Quantity by Application (2024-2034) & (K Units)
Table 87. China Hereditary Angioedema Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 88. China Hereditary Angioedema Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Hereditary Angioedema Treatment Sales Quantity by Company (2018-2024) & (K Units)
Table 90. APAC Hereditary Angioedema Treatment Revenue by Company (2018-2024) & (US$ Million)
Table 91. APAC Hereditary Angioedema Treatment Sales Quantity by Type (2018-2024) & (K Units)
Table 92. APAC Hereditary Angioedema Treatment Sales Quantity by Type (2024-2034) & (K Units)
Table 93. APAC Hereditary Angioedema Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 94. APAC Hereditary Angioedema Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Hereditary Angioedema Treatment Sales Quantity by Application (2018-2024) & (K Units)
Table 96. APAC Hereditary Angioedema Treatment Sales Quantity by Application (2024-2034) & (K Units)
Table 97. APAC Hereditary Angioedema Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 98. APAC Hereditary Angioedema Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Hereditary Angioedema Treatment Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 100. APAC Hereditary Angioedema Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 101. APAC Hereditary Angioedema Treatment Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Hereditary Angioedema Treatment Sales Quantity by Region (2018-2024) & (K Units)
Table 103. APAC Hereditary Angioedema Treatment Sales Quantity by Region (2024-2034) & (K Units)
Table 104. Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity by Company (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue by Company (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity by Type (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity by Type (2024-2034) & (K Units)
Table 108. Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity by Application (2018-2024) & (K Units)
Table 111. Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity by Application (2024-2034) & (K Units)
Table 112. Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 113. Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity by Country (2018-2024) & (K Units)
Table 118. Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity by Country (2024-2034) & (K Units)
Table 119. CSL Company Information
Table 120. CSL Description and Overview
Table 121. CSL Hereditary Angioedema Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 122. CSL Hereditary Angioedema Treatment Product and Services
Table 123. CSL Hereditary Angioedema Treatment SWOT Analysis
Table 124. CSL Recent Developments
Table 125. Pharming Group Company Information
Table 126. Pharming Group Description and Overview
Table 127. Pharming Group Hereditary Angioedema Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 128. Pharming Group Hereditary Angioedema Treatment Product and Services
Table 129. Pharming Group Hereditary Angioedema Treatment SWOT Analysis
Table 130. Pharming Group Recent Developments
Table 131. Shire plc (Takeda Pharmaceutical Company Limited) Company Information
Table 132. Shire plc (Takeda Pharmaceutical Company Limited) Description and Overview
Table 133. Shire plc (Takeda Pharmaceutical Company Limited) Hereditary Angioedema Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 134. Shire plc (Takeda Pharmaceutical Company Limited) Hereditary Angioedema Treatment Product and Services
Table 135. Shire plc (Takeda Pharmaceutical Company Limited) Hereditary Angioedema Treatment SWOT Analysis
Table 136. Shire plc (Takeda Pharmaceutical Company Limited) Recent Developments
Table 137. Ionis Pharmaceuticals Company Information
Table 138. Ionis Pharmaceuticals Description and Overview
Table 139. Ionis Pharmaceuticals Hereditary Angioedema Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 140. Ionis Pharmaceuticals Hereditary Angioedema Treatment Product and Services
Table 141. Ionis Pharmaceuticals Hereditary Angioedema Treatment SWOT Analysis
Table 142. Ionis Pharmaceuticals Recent Developments
Table 143. Attune Pharmaceuticals Company Information
Table 144. Attune Pharmaceuticals Description and Overview
Table 145. Attune Pharmaceuticals Hereditary Angioedema Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 146. Attune Pharmaceuticals Hereditary Angioedema Treatment Product and Services
Table 147. Attune Pharmaceuticals Hereditary Angioedema Treatment SWOT Analysis
Table 148. Attune Pharmaceuticals Recent Developments
Table 149. BioCryst Pharmaceuticals Company Information
Table 150. BioCryst Pharmaceuticals Description and Overview
Table 151. BioCryst Pharmaceuticals Hereditary Angioedema Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 152. BioCryst Pharmaceuticals Hereditary Angioedema Treatment Product and Services
Table 153. BioCryst Pharmaceuticals Hereditary Angioedema Treatment SWOT Analysis
Table 154. BioCryst Pharmaceuticals Recent Developments
Table 155. KalVista Pharmaceuticals Company Information
Table 156. KalVista Pharmaceuticals Description and Overview
Table 157. KalVista Pharmaceuticals Hereditary Angioedema Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 158. KalVista Pharmaceuticals Hereditary Angioedema Treatment Product and Services
Table 159. KalVista Pharmaceuticals Hereditary Angioedema Treatment SWOT Analysis
Table 160. KalVista Pharmaceuticals Recent Developments
Table 161. Key Raw Materials Lists
Table 162. Raw Materials Key Suppliers Lists
Table 163. Hereditary Angioedema Treatment Distributors List
Table 164. Hereditary Angioedema Treatment Customers List
Table 165. Hereditary Angioedema Treatment Market Trends
Table 166. Hereditary Angioedema Treatment Market Drivers
Table 167. Hereditary Angioedema Treatment Market Challenges
Table 168. Hereditary Angioedema Treatment Market Restraints
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. Hereditary Angioedema Treatment Product Picture
Figure 2. Global Hereditary Angioedema Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Hereditary Angioedema Treatment Market Share by Type in 2022 & 2034
Figure 4. C1 Estearse Inhibitors (Plasma Products, Recombinant Products) Product Picture
Figure 5. Selective Bradykinin B2 Receptor Antagonists (Firazyr) Product Picture
Figure 6. Kallikrein Inhibitors (Kalbitor, Takhzyro) Product Picture
Figure 7. Others (Conventional Drugs, Pipeline Drugs) Product Picture
Figure 8. Global Hereditary Angioedema Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Hereditary Angioedema Treatment Market Share by Application in 2022 & 2034
Figure 10. Hospital Pharmacies
Figure 11. Retail Pharmacies
Figure 12. Others (online pharmacies, mail pharmacies)
Figure 13. Hereditary Angioedema Treatment Report Years Considered
Figure 14. Global Hereditary Angioedema Treatment Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Hereditary Angioedema Treatment Revenue 2018-2034 (US$ Million)
Figure 16. Global Hereditary Angioedema Treatment Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Hereditary Angioedema Treatment Sales Quantity 2018-2034 (K Units)
Figure 18. Global Hereditary Angioedema Treatment Sales Quantity Market Share by Region (2018-2024)
Figure 19. Global Hereditary Angioedema Treatment Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Hereditary Angioedema Treatment Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. North America Hereditary Angioedema Treatment Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Hereditary Angioedema Treatment Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. Europe Hereditary Angioedema Treatment Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Hereditary Angioedema Treatment Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. China Hereditary Angioedema Treatment Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Hereditary Angioedema Treatment Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. APAC Hereditary Angioedema Treatment Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Hereditary Angioedema Treatment Sales Quantity in 2022
Figure 31. The Top 10 and Top 5 Players Market Share by Hereditary Angioedema Treatment Revenue in 2022
Figure 32. Hereditary Angioedema Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Hereditary Angioedema Treatment Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Hereditary Angioedema Treatment Revenue Market Share by Type (2018-2034)
Figure 35. Global Hereditary Angioedema Treatment Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Hereditary Angioedema Treatment Revenue Market Share by Application (2018-2034)
Figure 37. North America Hereditary Angioedema Treatment Revenue Market Share by Company in 2022
Figure 38. North America Hereditary Angioedema Treatment Sales Quantity Market Share by Company in 2022
Figure 39. North America Hereditary Angioedema Treatment Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Hereditary Angioedema Treatment Revenue Market Share by Type (2018-2034)
Figure 41. North America Hereditary Angioedema Treatment Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Hereditary Angioedema Treatment Revenue Market Share by Application (2018-2034)
Figure 43. North America Hereditary Angioedema Treatment Revenue Share by Country (2018-2034)
Figure 44. North America Hereditary Angioedema Treatment Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Hereditary Angioedema Treatment Sales Quantity Market Share by Company in 2022
Figure 48. Europe Hereditary Angioedema Treatment Revenue Market Share by Company in 2022
Figure 49. Europe Hereditary Angioedema Treatment Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Hereditary Angioedema Treatment Revenue Market Share by Type (2018-2034)
Figure 51. Europe Hereditary Angioedema Treatment Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Hereditary Angioedema Treatment Revenue Market Share by Application (2018-2034)
Figure 53. Europe Hereditary Angioedema Treatment Revenue Share by Country (2018-2034)
Figure 54. Europe Hereditary Angioedema Treatment Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 56. France Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 60. China Hereditary Angioedema Treatment Sales Quantity Market Share by Company in 2022
Figure 61. China Hereditary Angioedema Treatment Revenue Market Share by Company in 2022
Figure 62. China Hereditary Angioedema Treatment Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Hereditary Angioedema Treatment Revenue Market Share by Type (2018-2034)
Figure 64. China Hereditary Angioedema Treatment Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Hereditary Angioedema Treatment Revenue Market Share by Application (2018-2034)
Figure 66. APAC Hereditary Angioedema Treatment Sales Quantity Market Share by Company in 2022
Figure 67. APAC Hereditary Angioedema Treatment Revenue Market Share by Company in 2022
Figure 68. APAC Hereditary Angioedema Treatment Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Hereditary Angioedema Treatment Revenue Market Share by Type (2018-2034)
Figure 70. APAC Hereditary Angioedema Treatment Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Hereditary Angioedema Treatment Revenue Market Share by Application (2018-2034)
Figure 72. APAC Hereditary Angioedema Treatment Revenue Share by Region (2018-2034)
Figure 73. APAC Hereditary Angioedema Treatment Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 78. India Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Hereditary Angioedema Treatment Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Hereditary Angioedema Treatment Revenue Share by Country (2018-2034)
Figure 87. Brazil Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Hereditary Angioedema Treatment Revenue (2018-2034) & (US$ Million)
Figure 92. Hereditary Angioedema Treatment Value Chain
Figure 93. Hereditary Angioedema Treatment Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries